Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1~* Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Ability to swallow tablets~* Adequate bone marrow and organ function, as defined by the protocol~Exclusion Criteria:~* Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)~* Ocular melanoma~* Any significant acute or chronic medical illness~* Prior malignancy~* Other active malignancy requiring concurrent intervention~* Prior organ allograft or allogeneic bone marrow transplantation~* Participants with active, known, or suspected autoimmune disease~* Requirement for daily supplemental oxygen~* Uncontrolled or significant cardiovascular disease~* Pre-existing liver disease~* Gastrointestinal disease known to interfere with absorption~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation (Type: EXPERIMENTAL): BMS-986242 administered in combination with Nivolumab
- Dose Expansion (Type: EXPERIMENTAL): BMS-986242 administered in combination with Nivolumab

Based on this trial design, predict the completion outcome and termination type (if applicable).